Related Experiment Video
Updated: Oct 7, 2025

Testing Sensory and Multisensory Function in Children with Autism Spectrum Disorder
Published on: April 22, 2015
Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children
Sarah A Keim1,2,3, Abigail Jude4, Katie Smith4
1Nationwide Children's Hospital, 700 Children's Dr, Columbus, OH, 43205, USA. sarah.keim@nationwidechildrens.org.
Insights
This study investigated fatty acid (FA) supplementation for children with Autism Spectrum Disorder (ASD). Supplementation increased omega-3 and omega-6 levels and reduced a key inflammatory marker, showing promise for ASD management.
Area of Science:
- Neuroscience
- Biochemistry
- Pediatrics
Background:
- Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition.
- Altered fatty acid (FA) metabolism and inflammation are implicated in ASD.
- Targeting FA pathways may offer a novel therapeutic approach for ASD.
Purpose of the Study:
- To evaluate the efficacy and safety of omega-3 and omega-6 fatty acid supplementation in children with ASD.
- To assess the impact of FA supplementation on erythrocyte FA levels and plasma cytokine profiles.
- To determine the tolerability and adherence rates of FA supplementation in this pediatric population.
Main Methods:
- A double-blind, randomized controlled trial was conducted with children aged 2-6 years diagnosed with ASD.
- Participants received daily oral supplementation of omega-3 and omega-6 FAs or a placebo for 90 days.
- Erythrocyte FAs and plasma cytokines (IL-1β, IL-2, IFNγ) were measured via serial blood collections.
Main Results:
- FA supplementation significantly increased erythrocyte levels of omega-3 (EPA) and omega-6 (DHA).
- Treatment resulted in a significant reduction in plasma IL-2 levels compared to the placebo group.
- The FA supplementation was well-tolerated, with adherence rates exceeding 70%.
Conclusions:
- Omega-3 and omega-6 FA supplementation is a safe and tolerable intervention for children with ASD.
- The observed changes in FA levels and IL-2 suggest a potential immunomodulatory effect.
- Further research is warranted to investigate the impact of FA supplementation on core ASD symptoms.
Abstract:
This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6 years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90 days based on participant weight. Erythrocyte FAs and the cytokines, IL-1β, IL-2, IFNγ, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40 mol% for EPA and 1.62 mol% for DHA) and reduced IL-2 levels compared to placebo (- 0.17 pg/mL, 95% CI - 0.31, - 0.02, d = - 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209.
Related Concept Videos
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Atherosclerosis III: Management
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...

